General Drug Use-results Survey on PROPESS Vaginal Inserts in Treatment for Initiation of Cervical Ripening in Patients at Term (From 37 Completed Weeks of Gestation)

Primary outcomes

1. Incidence of adverse drug reactions associated with uterine hypercontractions

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

   Events defined as uterine hypercontractions were uterine hyperstimulation, uterine tachysystole, uterine hypertonus, uterine contractions abnormal.

2. Incidence of adverse drug reactions associated with foetal distress

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

   Events defined as foetal distress were abnormal labour affecting foetus, foetal heart rate disorder, foetal heart rate deceleration abnormality, bradycardia foetal, foetal heart rate abnormal, foetal heart rate decreased, foetal heart rate increased, tachycardia foetal, foetal acidosis, meconium in amniotic fluid, apgar score low, encephalopathy neonatal, arrhythmia neonatal, baseline foetal heart rate variability disorder, bradycardia neonatal, foetal arrhythmia, nonreassuring foetal heart rate pattern, cyanosis neonatal, infantile apnoea, neonatal anoxia, neonatal asphyxia, neonatal hypoxia, neonatal respiratory depression, foetal distress syndrome, foetal monitoring abnormal, neonatal respiratory distress syndrome, neonatal respiratory distress.

3. Incidence of adverse drug reactions of foetal distress, uterine rupture, cervical laceration and amniotic fluid embolus in patients with uterine hypercontractions

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

4. Incidence of adverse drug reactions by background factors affecting the occurrence of foetal distress

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

   Adverse drug reactions incidence rate by background factors such as patient age, height, weight, smoking history, medical history, pregnancy related disease, history of surgery on the uterus and cervix, presence or absence of uterine hypercontractions at the time of the previous parturition and concomitant medications, affecting the occurrence of foetal distress will be presented.

5. Incidence of adverse drug reactions

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

6. Incidence of serious adverse events

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

7. Incidence of adverse drug reactions by background factors affecting the overall safety of the product

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

   Adverse drug reactions incidence rate by background factors such as patient age, height, weight, smoking history, medical history, history of surgery on the uterus and cervix, presence or absence of uterine hypercontractions at the time of the previous parturition and concomitant medications, affecting the overall safety of the product will be presented.

8. Incidence of adverse drug reactions/adverse events in the foetuses and newborns

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer

9. Percentage of newborns with an Apgar score of less than 7 at 5 minutes after parturition

   Time frame: From administration of the drug to 24 hours after administration of the drug or 2 hours after birth whichever is longer